BioMarin Pharmaceutical (NASDAQ:BMRN) Rating Reiterated by Cantor Fitzgerald theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Xponance Inc. cut its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 2.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 8,966 shares of the biotechnology company’s stock after selling 203 shares during the quarter. Xponance […]
BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) had its target price lowered by Citigroup from $94.00 to $91.00 in a research note published on Thursday morning, Benzinga reports. Citigroup currently has a neutral rating on the biotechnology company’s stock. Several other research analysts have also issued reports on BMRN. Royal Bank of Canada restated a sector […]
BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) had its target price decreased by research analysts at Morgan Stanley from $115.00 to $112.00 in a research note issued to investors on Friday, Benzinga reports. The brokerage currently has an “overweight” rating on the biotechnology company’s stock. Morgan Stanley’s price target indicates a potential upside of 37.34% […]
BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) updated its FY24 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of $2.75-2.95 for the period, compared to the consensus estimate of $2.59. The company issued revenue guidance of $2.7-2.8 billion, compared to the consensus revenue estimate of $2.75 billion. BioMarin Pharmaceutical also updated […]